IN8bio
INAB
13 hedge funds and large institutions have $12.2M invested in IN8bio in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.32% more ownership
Funds ownership: 0% → 0.32% (+0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$6.63M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.11M |
| 3 |
BRF
B. Riley Financial
Los Angeles,
California
|
+$2.13M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$937K |
| 5 |
VC
Voss Capital
Houston,
Texas
|
+$669K |
Top Sellers
INAB Hedge Fund Activity: Q3 2021 in Review
13 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in IN8bio (INAB) for Q3 2021, worth a combined $12.2M.
Buyers outnumbered sellers: 13 funds opened new INAB positions and 0 closed out — a net gain of 13 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Capital World Investors, opening a new position worth an estimated $6.63M.
- 13 institutional investors held IN8bio (INAB) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $12.2M of IN8bio stock for Q3 2021.
- 13 funds opened new IN8bio positions in Q3 2021 and 0 closed out, a net change of +13 holders.
- The largest IN8bio buyer in Q3 2021 was Capital World Investors, an estimated $6.63M added.
Based on aggregated 13F filings for Q3 2021.